Alternative Blood Tests Match Gold Standard for Diabetes Monitoring

This study addresses a critical need in diabetes care by evaluating whether alternative blood biomarkers can match the performance of HbA1c, the current gold standard for diabetes monitoring. The research is particularly important as HbA1c has limitations in certain populations and clinical scenarios.

Researchers analyzed data from 552 adults with type 2 diabetes (mean age 74, 53% women, 36% Black) who wore continuous glucose monitors for up to two weeks. They compared four blood biomarkers - HbA1c, glycated albumin, fructosamine, and 1,5-anhydroglucitol (1,5-AG) - against CGM-defined metrics of glucose control.

The key finding was that glycated albumin and fructosamine performed remarkably similarly to HbA1c. All three biomarkers showed strong correlations with average CGM glucose levels (r=0.72 for HbA1c, r=0.64 for both glycated albumin and fructosamine). They were equally effective at detecting time spent above target glucose ranges, with c-statistics ranging from 0.85 to 0.94 for identifying poor glycemic control.

These results have significant clinical implications. Glycated albumin and fructosamine could serve as valuable alternatives when HbA1c is unreliable, such as in patients with hemoglobinopathies, recent blood transfusions, or conditions requiring shorter-term glucose monitoring. The study's diverse population strengthens the generalizability of findings across different demographic groups.

However, the cross-sectional design limits understanding of how these biomarkers perform over time, and the relatively well-controlled study population may not represent all diabetes patients in clinical practice.